F Kamin1, P S Rommer2, M Abu-Mugheisib3, W Koehler4, F Hoffmann5, A Winkelmann6, R Benecke6, U K Zettl6. 1. 1] Department of Neurology, University of Rostock, Rostock, Germany [2] Department of Pathology, MVZ Hochstraße, Brandenburg an der Havel, Germany. 2. 1] Department of Neurology, University of Rostock, Rostock, Germany [2] Department of Neurology, Medical University of Vienna, Vienna, Austria. 3. 1] Department of Neurology, University of Rostock, Rostock, Germany [2] Department of Neurology, Klinikum Braunschweig, Braunschweig, Germany. 4. Saechsisches Krankenhaus Hubertusburg, Wermsdorf, Germany. 5. Staedtisches Krankenhaus Martha-Maria Halle-Doelau, Halle, Germany. 6. Department of Neurology, University of Rostock, Rostock, Germany.
Abstract
OBJECTIVES: Multiple sclerosis (MS) is an autoimmune disease affecting young people and is a major cause of disability. In the course of time, disability progresses and symptoms like spasticity may occur. Spasticity is a major cost factor in MS patients. Various agents are approved for the treatment of spasticity, but each of those agents may have several side effects. Intrathecally administered steroids (triamcinolone-acetonide (TCA)) may be efficient in treating spasticity in patients with lesions in the spinal cord and no response to first-line therapeutics. The aim of this study is to show effects of TCA treatment on clinical parameters in patients with MS. METHODS: This multicentre open label study included 54 patients with MS. The clinical outcome parameters were spasticity, disability, maximum walking distance, bladder function and quality of life. All patients received physiotherapy in addition to TCA treatment to obtain optimal effects on clinical parameters. RESULTS: Spasticity, maximum walking distance as well as disability improved significantly (P ⩽ 0.001) during TCA applications. Bladder function improved in every seventh patient. CONCLUSION: We observed the effects of intrathecally administered TCA on different clinical parameters including bladder function. TCA administration is a safe method to treat different symptoms in MS patients. Longitudinal trials with repeated TCA cycles are needed to show long-term effects. Besides TCA treatment, physiotherapy contributes to the improvement of clinical parameters.
OBJECTIVES:Multiple sclerosis (MS) is an autoimmune disease affecting young people and is a major cause of disability. In the course of time, disability progresses and symptoms like spasticity may occur. Spasticity is a major cost factor in MSpatients. Various agents are approved for the treatment of spasticity, but each of those agents may have several side effects. Intrathecally administered steroids (triamcinolone-acetonide (TCA)) may be efficient in treating spasticity in patients with lesions in the spinal cord and no response to first-line therapeutics. The aim of this study is to show effects of TCA treatment on clinical parameters in patients with MS. METHODS: This multicentre open label study included 54 patients with MS. The clinical outcome parameters were spasticity, disability, maximum walking distance, bladder function and quality of life. All patients received physiotherapy in addition to TCA treatment to obtain optimal effects on clinical parameters. RESULTS:Spasticity, maximum walking distance as well as disability improved significantly (P ⩽ 0.001) during TCA applications. Bladder function improved in every seventh patient. CONCLUSION: We observed the effects of intrathecally administered TCA on different clinical parameters including bladder function. TCA administration is a safe method to treat different symptoms in MSpatients. Longitudinal trials with repeated TCA cycles are needed to show long-term effects. Besides TCA treatment, physiotherapy contributes to the improvement of clinical parameters.
Authors: V Hoffmann; W Kuhn; S Schimrigk; S Islamova; K Hellwig; C Lukas; N Brune; D Pöhlau; H Przuntek; T Müller Journal: Eur J Neurol Date: 2006-01 Impact factor: 6.089
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp Journal: Nervenarzt Date: 2021-07-23 Impact factor: 1.214
Authors: Paulus Stefan Rommer; Frank Kamin; Mazen Abu-Mugheisib; Wolfgang Koehler; Frank Hoffmann; Alexander Winkelmann; Reiner Benecke; Uwe Klaus Zettl Journal: CNS Neurosci Ther Date: 2015-11-20 Impact factor: 5.243
Authors: Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Julia Brenmoehl; Uwe Klaus Zettl Journal: Front Endocrinol (Lausanne) Date: 2021-01-05 Impact factor: 5.555
Authors: Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Manuela Bastian; Julia Brenmoehl; Ina Schröder; Holger S Willenberg; Martin Reincke; Uwe Klaus Zettl Journal: Front Endocrinol (Lausanne) Date: 2020-08-27 Impact factor: 5.555